Enzo Biochem (ENZB) AI Stock Analysis

• Market Cap: $27.77M
• Dividend Yield: N/A
• Average Volume (3M): 51.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.61
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 125
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.05
• Shares Outstanding: 52,402,805
• 10 Day Avg. Volume: 46,476
• 30 Day Avg. Volume: 51,559
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: $0.50 ▼(-5.66%Downside)

Enzo Biochem's stock score is primarily influenced by its financial performance challenges, including negative profit margins and cash flow issues, despite a stable balance sheet. Technical indicators offer a neutral outlook, while valuation metrics highlight concerns due to negative earnings.

Enzo Biochem Business Overview & Revenue Model

Company Description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

How the Company Makes Money

Enzo Biochem generates revenue primarily through its two operating segments. Enzo Clinical Labs earns money by providing diagnostic and clinical laboratory testing services to physicians, medical centers, and other healthcare providers. This includes routine blood tests, molecular diagnostics, and specialized testing services. Enzo Life Sciences generates revenue by selling a wide range of life sciences products, including reagents, assays, and kits to academic institutions, biopharmaceutical companies, and laboratories worldwide. The company also benefits from partnerships and licensing agreements that leverage its proprietary technologies and intellectual property, contributing to its earnings.

Enzo Biochem Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement		Total Revenue
	Gross Profit
	EBIT
	EBITDA
	Net Income Common Stockholders
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
	Total Assets
	Total Debt
	Net Debt
	Total Liabilities
	Stockholders Equity
Cash Flow		Free Cash Flow
	Operating Cash Flow
	Investing Cash Flow
	Financing Cash Flow

Enzo Biochem Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENZB, the sentiment is Negative. The current price of 0.53 is below the 20-day moving average (MA) of 0.58, above the 50-day MA of 0.51, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 42.08 is Neutral, neither overbought nor oversold. The STOCH value of 28.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENZB.

Enzo Biochem Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TVRD	57 Neutral	$241.23M	―	-414.88%	―	-65.96%	40.80%
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
ENZB	51 Neutral	$27.77M	―	-13.95%	―	―	―
IGC	45 Neutral	$24.10M	―	-115.06%	―	1.64%	50.63%
ENLV	36 Underperform	$26.00M	―	-60.35%	―	―	53.95%
BCAB	35 Underperform	$23.45M	―	-246.21%	―	―	44.38%
NRSN	30 Underperform	$56.37M	―	-2880.11%	―	―	31.09%